Narla, Goutham

All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase

Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 312

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition

Parikh, A., Lee, C., Joseph, P., Marchini, S., Baccarini, A., Kolev, V., Romualdi, C., Fruscio, R., Shah, H., Wang, F., et al. (2014) · Nature Communications

MicroRNA in disease regulationTGF-β signaling in diseases

Cited by 258

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., Izadmehr, S., Mazhar, S., Wiredja, D. D., O’Connor, C. M., et al. (2017) · Journal of Clinical Investigation

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 196

Selective PP2A enhancement through biased heterotrimer stabilization

Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 176

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 149

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research

PI3K/AKT/mTOR signaling in cancerPancreatic and Hepatic Oncology Research

Cited by 85

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer

McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 78

In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma

Narla, G., Kremer-Tal, S., Matsumoto, N., Zhao, X., Yao, S., Kelley, K., Tarocchi, M., & Friedman, S. L. (2007) · Oncogene

Kruppel-like factors researchCancer-related Molecular Pathways

Cited by 77

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

Laine, A., Nagelli, S. G., Farrington, C., Butt, U., Cvrljevic, A. N., Vainonen, J. P., Feringa, F. M., Grönroos, T. J., Gautam, P., Khan, S., et al. (2020) · Cancer Research

DNA Repair MechanismsBreast Cancer Treatment Studies

Cited by 54

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors

O’Connor, C. M., Leonard, D., Wiredja, D., Avelar, R. A., Wang, Z., Schlatzer, D., Bryson, B., Tokala, E., Taylor, S. E., Upadhyay, A., et al. (2020) · Oncogene

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 48